ArticleCellular and molecular life sciences : CMLS2026
Histone methyltransferase EZH2 drives podocyte injury and senescence in diabetic nephropathy through STAT3 activation.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAs a common secondary nephropathy, diabetic nephropathy (DN) is closely related to podocyte senescence. Histone methyltransferase enhancer of zeste homolog 2 (EZH2) participates in the regulation of cellular proliferation, apoptosis, and senescence. Recently, the non-histone role of EZH2 has attracted much attention. It was reported that EZH2 can directly combine with signal transducer and activator of transcription 3 (STAT3) thereby enhancing its activity. However, the association between EZH2 and STAT3 in podocyte senescence remains unclear.
methodsTo clarify the association between EZH2 and STAT3 and their functions in podocyte injury and senescence in DN, we established db/db mice and cultured mouse podocyte cells (MPCs) exposed to high glucose (HG) as DN models. EZH2 was regulated genetically and pharmacologically in this study and changes in indicators related to podocyte injury and aging were detected. KEY
findingsElevated levels of EZH2, inflammatory markers, and reduced podocyte marker proteins were observed in db/db mice and HG-cultured MPCs. Additionally, aggravated podocyte senescence was observed in the DN group. Pharmacological inhibition of EZH2 by GSK126 alleviated kidney aging and podocyte injury markers by approximately 54% in db/db mice. Moreover, we confirmed that EZH2 can bind to STAT3 and increase the methylation of its lysine residues, thereby promoting its activity. However, rescue experiments in vivo and in vitro revealed that the beneficial effect of EZH2 downregulation was counteracted by overexpression of STAT3.
conclusionMechanistically, EZH2 interacted with STAT3 and enhanced its activation, in association with increased lysine methylation of STAT3. Together, our findings identify EZH2-STAT3 signaling as a key driver of podocyte injury and senescence in DN and suggest that targeting EZH2 may represent a promising therapeutic strategy for DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.